Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0141


PLX4032: A novel effective anti-melanoma drug and new ways to overcome resistance

Dimitrios H. Roukos, M.D, PhD.

Affiliation: Personalized Cancer Medicine, Biobank, Ioannina University School of Medicine, Ioannina, 45110 Greece.



For the first time a too high response rate of 80% to the novel anti-melanoma drug PLX4032 has been demonstrated. In the August 2010 issue of NEJM , treatment of metastatic melanoma with PLX4032 in selected BRAF (V600E) mutation patients resulted in complete or partial tumor regression in the majority of patients. But this drug activity worked for a mean of 7 months only [1]. Two more recent studies in Nature report mechanisms driving resistance aiming at the discovery of new 'druggable' targets.

The expression of COT, a protein encoding by MAP3K8 gene, was associated with de novo and acquired resistance [2]. Reactivation of the B-RAF signaling pathway or stimulation tumour-cell growth mediated by a different protein found to be related to PLX4032 acquired resistance by another group [3]. Here I discuss the future perspectives of potential understanding mechanisms resistance including signaling pathways networks towards a new generation of more active drugs overcoming resistance.

(Citation: Gastric & Breast Cancer 2010 Oct ; 9(4): 170-174)

This article consists of 5 pages and 3 figures .


You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 25 November 2010